Elosulfase Alfa

證據等級: L5

預測適應症: 9 個

Elosulfase Alfa: From Morquio A Syndrome (MPS IVA) to Lysosomal Storage Disease with Skeletal Involvement

One-Sentence Summary

Elosulfase alfa (DrugBank DB09051) is a recombinant enzyme replacement therapy already known in the literature as the approved treatment for Morquio A syndrome (Mucopolysaccharidosis IVA, MPS IVA). Among 9 TxGNN-predicted indications reviewed, only “lysosomal storage disease with skeletal involvement” (TxGNN rank 2, score 99.59%) maps mechanistically onto this known use, supported by 6 publications (no registered clinical trials found under this exact disease label). The model’s top-ranked candidate, Scheie syndrome, and five other high-scoring candidates (Hurler syndrome, Sanfilippo syndrome, and four ultra-rare congenital syndromes) were reviewed and found to lack any credible mechanistic or evidentiary link — most involve enzyme targets unrelated to GALNS, and several literature/trial hits are disease-label mismatches rather than genuine evidence.

Quick Overview

Item	Content
Original Indication	Morquio A Syndrome (MPS IVA) — per literature, not present in local regulatory license data
Predicted New Indication	Lysosomal storage disease with skeletal involvement (clinically corresponds to MPS IVA/Morquio A)
TxGNN Prediction Score	99.59%
Evidence Level	L3
US Market Status	未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Structured MOA data is not available in the regulatory data source (Data Gap DG002). However, based on the literature gathered for this evaluation, elosulfase alfa is a recombinant human N-acetylgalactosamine-6-sulfatase (GALNS) that directly replaces the enzyme deficient in Morquio A syndrome, breaking down the accumulated keratan sulfate and chondroitin-6-sulfate that drive the disease’s progressive skeletal dysplasia.

The TxGNN-predicted label “lysosomal storage disease with skeletal involvement” is a broader disease-ontology term whose supporting literature is, in substance, entirely about MPS IVA/Morquio A — the drug’s already-known approved use. This is therefore best read as a confirmatory finding (the model correctly recovering an established indication) rather than a novel repurposing opportunity, which is consistent with original_indications being an empty/unpopulated field in this evidence pack rather than a true absence of indication.

Of the other 8 predicted indications in this candidate set, none held up on review: Scheie syndrome, Hurler syndrome, and Sanfilippo syndrome are all caused by deficiencies in enzymes other than GALNS (alpha-L-iduronidase or heparan-sulfate-pathway enzymes), so there is no substrate or mechanistic overlap, and their attached literature/trial hits were found to be generic MPS cohort studies or unrelated Morquio A trial data rather than disease-specific evidence. The remaining four candidates (rare congenital ptosis/ocular-motility/Horner syndromes) are structural developmental disorders with no known link to GAG metabolism, no literature, and no trials — TxGNN score alone (L5, model prediction only).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41088244	2025	Review	Orphanet J Rare Dis	Reviews recent MPS IVA (Morquio A) treatment advances; confirms ERT with elosulfase alfa is currently the only approved treatment, noting its limited effect on bone pathology
39541578	2024	Review (meta-analysis protocol)	JMIR Res Protocols	Protocol for phenotype-genotype correlation meta-analysis in Morquio A syndrome
25496828	2015	Review/Clinical guidance	Mol Genet Metab	Diagnostic evaluation, monitoring, and perioperative management of spinal cord compression in Morquio syndrome
38831290	2024	Cohort/Case series	BMC Med Genomics	Describes delayed diagnosis in mild/atypical MPS IVA presentations
36000290	2022	Case report/genetic	Ann Hum Genet	Novel splicing variant identified in the GALNS gene in an MPS IVA patient
25944767	2015	Diagnostic method study	Clin Chim Acta	Dried-leukocyte filter paper method for detecting Pompe, Gaucher, and Morquio A disease

US Market Information

Elosulfase alfa is not currently marketed in this jurisdiction (market status: 未上市, 0 licenses on file). No authorization records are available to summarize.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN-predicted indication “lysosomal storage disease with skeletal involvement” is mechanistically direct and substantively corresponds to elosulfase alfa’s known role as ERT for Morquio A syndrome/MPS IVA, but the evidence available here is limited to observational and mechanistic literature (L3) with no clinical trials retrieved under this exact disease label and no local regulatory or safety data. All other candidates in this evidence pack (Scheie, Hurler, Sanfilippo syndromes, and four rare congenital syndromes) failed mechanistic review and are recommended Hold.

To proceed, the following is needed:

Confirm regulatory/label status for MPS IVA specifically (source: official prescribing information/TFDA equivalent), since original_indications is currently empty in this evidence pack
Formal MOA field data from DrugBank (currently Data Gap DG002)
TFDA warnings/contraindications (currently Blocking Data Gap DG001) before any safety assessment (S1) can proceed
If pursuing skeletal-involvement LSDs beyond MPS IVA as a genuine new indication, disease-specific clinical trial search (current searches returned 0 trials)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.